title: Current techniques of hyperthermic isolated limb perfusion for malignant melanoma.
abstract: A retrospective study was conducted examining 25 patients with malignant melanoma who were treated by our new protocol for hyperthermic isolated limb perfusion. The characteristics of our techniques include: a lower priming volume of the extracorporeal circuit; a therapeutic temperature range of 40-41 degrees C with 60 min hyperthermic perfusion; a nominal perfusion flow rate of 500 ml/min in the lower limb and 200 ml/min in the upper limb; and combined carboplatin with interferon-beta as the adjuvant chemotherapy drug. In the lower extremity group, the arterial cannula size ranged from 8 to 14 F, while the venous cannula size ranged from 14 to 16 F. In the upper limb group, the arterial cannula size ranged from 6 to 8F and the venous cannula size ranged from 10 to 12F. No patient required any homologous blood transfusion postoperatively. No operative death or major complications occurred during the early postoperative period, confirming the safety of this treatment. Both optimal cannula size selection and maintaining perfusion temperature below 41 degrees C were judged to be important in elimination of vascular and deep tissue injury.
authors.affiliation: Department of Cardiovascular Surgery, Kyushu University Faculty of Medicine, Fukuoka, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Tominaga
authors.forename: H
authors.initials: H
authors.lastname: Kohno
authors.forename: H
authors.initials: H
authors.lastname: Mayumi
authors.forename: K
authors.initials: K
authors.lastname: Shiraishi
authors.forename: S
authors.initials: S
authors.lastname: Nagae
authors.forename: J
authors.initials: J
authors.lastname: Nakayama
authors.forename: H
authors.initials: H
authors.lastname: Yasui
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016190:Carboplatin / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D005112:Extracorporeal Circulation; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D016899:Interferon-beta / Q000627:therapeutic use; D008197:Lymph Node Excision; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D016899:Interferon-beta; D016190:Carboplatin